The short answer
"Triple-negative" describes a breast cancer that tests negative for three receptors: estrogen receptor (ER), progesterone receptor (PR), and HER2. Because it lacks these targets, hormone therapy and HER2-targeted drugs generally don't work — so chemotherapy, and increasingly immunotherapy and other approaches, are the mainstays. It describes the cancer's biology, not its stage, and effective treatments exist.
Triple-negative = negative for ER, PR, and HER2 on testing.
Hormone therapy and HER2-targeted drugs usually aren't options because those targets are absent.
Chemotherapy is a mainstay; immunotherapy and other treatments may be options depending on the situation.
It describes biology, not stage — triple-negative cancers can be early or advanced.
Choose how you want to understand this
The full explanation.
Where you'll see this phrase
You'll see this phrase on a breast cancer pathology report. It comes after receptor testing. It might read "ER negative, PR negative, HER2 negative — triple-negative breast cancer." This is often shortened to TNBC.
What it means in plain language
Doctors test breast cancers for three things. Treatment can target all three: the estrogen receptor, the progesterone receptor, and HER2, a growth-related protein. When all three come back absent, the cancer is called triple-negative. It simply lacks these particular targets.
Why it matters
These three receptors matter because certain drugs are built to act on them. Without the receptors, hormone therapy and HER2-targeted drugs are not expected to work. That is why triple-negative cancers are treated mainly with chemotherapy. Depending on your situation, immunotherapy, drugs for specific mutations, or a clinical trial may also be options.
A newer option: immunotherapy before surgery
For high-risk, early-stage triple-negative breast cancer, the FDA approved a new option. It is an immunotherapy drug called pembrolizumab. Doctors combine it with chemotherapy before surgery. Then they continue it alone after surgery. In the trial behind this approval, adding pembrolizumab helped. It lowered the rate of cancer coming back or getting worse. About 16 in 100 people on the combination had this happen. About 24 in 100 did on chemotherapy alone. This option depends on your stage. It also depends on your situation. Not everyone with triple-negative breast cancer qualifies.
What it does not mean
Triple-negative does not mean "untreatable." Effective treatments exist. Research in this area is active. It also does not describe the stage of the cancer. Triple-negative cancers can be caught early too.
The BRCA connection
Triple-negative breast cancer is more common in people who carry an inherited BRCA1 mutation. This is more likely than in breast cancer overall. Because of this link, genetic testing is often recommended after a triple-negative diagnosis. This holds even without a strong family history. A BRCA result can also open up specific targeted drugs. These are called PARP inhibitors.
What context is still needed
Triple-negative is a description of biology, not a full plan. Your actual treatment depends on stage, grade, genetic testing, and your overall health. Your oncologist puts all of this together with you.
Is this urgent?
A triple-negative diagnosis is not an emergency by itself. But treatment usually starts within a few weeks, since these cancers can grow relatively fast. If you have not heard a treatment plan within two to three weeks, ask your team for a timeline.
What to ask your team
- What treatments are recommended for my triple-negative cancer, and why?
- Am I a candidate for immunotherapy, and at what point in my treatment?
- Should I have genetic testing, including for BRCA mutations?
- How soon should treatment start?
Why timing matters for the immunotherapy option
The pembrolizumab option for early-stage triple-negative breast cancer is specifically approved for use before surgery, continued after. It is not generally added after the fact once surgery and chemotherapy are already finished on their own. This means the decision about immunotherapy typically needs to happen early, right after diagnosis and staging, before your treatment sequence begins. If you are newly diagnosed with triple-negative breast cancer, ask about this option as early as possible in your workup, since waiting can close the door on it even if you would otherwise have qualified.
Clinical trials are worth asking about
Triple-negative breast cancer is an area of active research. Several new drug classes are being studied specifically for it. Standard options are more limited than for hormone-receptor-positive cancer. Because of this, clinical trials are often a bigger part of the conversation. This applies both at diagnosis and if the cancer returns. Ask your oncologist directly whether any trials are open for your situation. Also ask whether a referral to a larger academic cancer center might open up more trial options.
How treatment response is tracked
For triple-negative breast cancer treated before surgery, doctors watch something specific. They track how much cancer remains at the time of surgery. This is called the pathologic response. A pathologic complete response means no invasive cancer is found in the removed tissue. This result is linked with a notably better long-term outlook. That's compared with finding residual cancer at surgery. If residual cancer is found, more chemotherapy after surgery is sometimes added. This addresses the leftover cancer directly. This makes the surgical pathology report an important checkpoint. It matters just as much as the original biopsy in your overall treatment course.
Sources
Words to know
Tap any term to see what it means.
Common questions
Is triple-negative breast cancer always aggressive?
Triple-negative cancers can grow faster on average, but they vary a lot person to person. Stage, grade, and how the cancer responds to treatment all matter, and many people are treated successfully.
Why can't I take hormone therapy?
Hormone therapies work by blocking estrogen or progesterone signals. If the cancer is ER- and PR-negative, there's no receptor for those drugs to act on, so they aren't expected to help.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Plain-language definitions for the words on your report.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Last updated: 2026-08-05Next planned review: 2027-07-12
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
General education. Low-risk educational or organizational content. Medical facts are cited to authoritative sources.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share